Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.

Science (New York, N.Y.) - 5 Feb 2016

Green Eric M, Wakimoto Hiroko, Anderson Robert L, Evanchik Marc J, Gorham Joshua M, Harrison Brooke C, Henze Marcus, Kawas Raja, Oslob Johan D, Rodriguez Hector M, Song Yonghong, Wan William, Leinwand Leslie A, Spudich James A, McDowell Robert S, Seidman J G, Seidman Christine E

Abstract excerpt

Hypertrophic cardiomyopathy (HCM) is an inherited disease of heart muscle that can be caused by mutations in sarcomere proteins. Clinical diagnosis depends on an abnormal thickening of the heart, but the earliest signs of disease are hyperdynamic contraction and impaired relaxation. Whereas some in vitro studies of power generation by mutant and wild-type sarcomere proteins are consistent with mutant sarcomeres...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzylamines
Share to Cardiac Myosins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiomyopathy, Hypertrophic, Familial

Share to Heart Ventricles

Share to Myocardial Contraction

Share to Myosin Heavy Chains

Share to Sarcomeres

Share to Uracil

Source

Open in PubMed Open full text

Identifiers

PMID: 26912705
DOI: 10.1126/science.aad3456
PMCID: PMC4784435

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.PMID 26912705Read ↗

Targets for therapy in sarcomeric cardiomyopathies.Semantic proximity Read ↗

Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.Semantic proximity Read ↗

Direct Sarcomere Modulators Are Promising New Treatments for CardiomyopathiesSemantic proximity Read ↗

Targeting the sarcomere in inherited cardiomyopathies.Semantic proximity Read ↗

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Semantic proximity Read ↗

<i>MYBPC3</i> Mutations cause Hypertrophic Cardiomyopathy by Dysregulating Myosin: Implications for TherapySemantic proximity Read ↗

Preventative therapeutic approaches for hypertrophic cardiomyopathy.Semantic proximity Read ↗

Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEFSemantic proximity Read ↗

Toward transcriptional therapies for the failing heart: chemical screens to modulate genesSemantic proximity Read ↗

Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.Semantic proximity Read ↗

Sarcomere neutralization in inherited cardiomyopathy: small-molecule proof-of-concept to correct hyper-Ca2+-sensitive myofilaments.Semantic proximity Read ↗

Inhibition of Jumonji demethylases reprograms severe dilated cardiomyopathy and prolongs survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.